---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-023538"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-07-14T20:21:27+00:00"
generated_at: "2026-07-14T20:22:11.719820+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CervoMed presents new neflamapimod data at AAIC 2026; supports Phase 3 dose 50 mg TID in DLB

## Summary
- New analyses from Phase 2b RewinD-LB show neflamapimod slowed worsening in DLB patients with low pTau181 and adequate drug exposure.
- Neflamapimod produced durable slowing of basal forebrain atrophy over 48 weeks and increased basal forebrain connectivity vs placebo.
- Phase 2 study of 80 mg BID met primary safety, tolerability, and PK objectives; encouraging secondary clinical activity findings.
- PK-PD analysis identifies plasma trough threshold ~4 ng/mL; 50 mg TID dose expected to achieve threshold in ~90% of patients.
- Company gained alignment with FDA, EMA, MHRA, and PMDA for planned Phase 3 trial in DLB.

## SEC filing metadata
- accession: 0001437749-26-023538
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-07-14T20:21:27+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/0001437749-26-023538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/crvo20260714_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-023538
- JSON: https://secwatch.observer/filing/0001437749-26-023538.json
- Plain text: https://secwatch.observer/filing/0001437749-26-023538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.